Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $720.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target upped by investment analysts at Bank of America from $710.00 to $720.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “underperform” rating on the biopharmaceutical company’s stock. Bank of America‘s price target would suggest a potential downside of 20.42% from the stock’s previous close.

Several other research firms have also commented on REGN. Barclays raised their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective on the stock. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Finally, Truist Financial reaffirmed a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $970.57.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $904.70 on Friday. Regeneron Pharmaceuticals has a 52-week low of $684.80 and a 52-week high of $998.33. The stock has a market capitalization of $99.30 billion, a price-to-earnings ratio of 26.03, a price-to-earnings-growth ratio of 2.69 and a beta of 0.11. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $957.56 and its 200-day simple moving average is $889.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter last year, the firm earned $10.96 earnings per share. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals will post 38.18 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Joseph L. Goldstein sold 2,707 shares of the business’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now directly owns 6,382 shares in the company, valued at approximately $6,062,900. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Joseph L. Goldstein sold 2,707 shares of the company’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the sale, the director now owns 6,382 shares of the company’s stock, valued at $6,062,900. The disclosure for this sale can be found here. Insiders have sold a total of 13,729 shares of company stock valued at $13,124,641 in the last three months. 8.83% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Riverview Trust Co bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $71,000. Gateway Investment Advisers LLC boosted its holdings in Regeneron Pharmaceuticals by 13.7% in the first quarter. Gateway Investment Advisers LLC now owns 1,337 shares of the biopharmaceutical company’s stock worth $1,287,000 after purchasing an additional 161 shares in the last quarter. Harbor Investment Advisory LLC boosted its holdings in Regeneron Pharmaceuticals by 1.0% in the first quarter. Harbor Investment Advisory LLC now owns 3,708 shares of the biopharmaceutical company’s stock worth $3,569,000 after purchasing an additional 35 shares in the last quarter. Global Assets Advisory LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $339,594,000. Finally, Range Financial Group LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $229,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.